Experts at the University of Cardiff have identified a novel immune cell receptor that holds promise for transforming cancer treatments.
Immunotherapy harnesses the body's natural defenses against cancer, with T lymphocytes—key white blood cells—playing a central role. These cells expertly detect and eliminate defective or foreign invaders, combating infections and diseases.
CAR-T therapy exemplifies this approach: T cells are extracted from a patient's blood, genetically engineered in the lab to target cancer cells precisely, expanded, and reinfused. Drawing from years of clinical research, this method has shown real-world success.
Yet challenges persist. Modified T cells target only select cancer types, and their primary receptor, human leukocyte antigen (HLA), varies across individuals, demanding personalized treatments.
A potential game-changer emerges from Cardiff University researchers, who discovered a new T-cell receptor.
Dubbed MR1, this receptor functions like HLA but remains consistent across people, potentially enabling off-the-shelf therapies for broad populations.
While tested only in mice so far, the findings are compelling. Rodents engineered with cancers of the lung, skin, blood, colon, breast, bone, prostate, ovary, kidney, and cervix exhibited tumor regression and extended survival compared to untreated controls.
Human efficacy remains unproven, but MR1 raises hopes for versatile T cells tackling diverse cancers in many patients. Next steps include safety validation and deeper molecular insights before clinical trials.
Source
Related Articles:
